Literature DB >> 3315618

Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.

B Nunn1, A Esmail, R Fears, H Ferres, R Standring.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3315618     DOI： 10.2165/00003495-198700333-00013

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  8 in total

1.  THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION.

Authors:  A P FLETCHER; N ALKJAERSIG; S SHERRY; E GENTON; J HIRSH; F BACHMANN
Journal:  J Lab Clin Med       Date:  1965-05

Review 2.  Thrombolytic therapy in the eighties.

Authors:  M Verstraete; D Collen
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

3.  Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.

Authors:  F Van de Werf; M Nobuhara; D Collen
Journal:  Ann Intern Med       Date:  1986-03       Impact factor: 25.391

4.  Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.

Authors:  C Korninger; J M Stassen; D Collen
Journal:  Thromb Haemost       Date:  1981-10       Impact factor: 5.249

5.  [Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].

Authors:  P Doenecke; H Schwerdt; P Hellstern; E Wenzel; L Bette
Journal:  Klin Wochenschr       Date:  1986-08-01

6.  Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.

Authors:  M Been; D P de Bono; A L Muir; F E Boulton; R Fears; R Standring; H Ferres
Journal:  Int J Cardiol       Date:  1986-04       Impact factor: 4.164

7.  High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.

Authors:  R L Mentzer; A Z Budzynski; S Sherry
Journal:  Am J Cardiol       Date:  1986-06-01       Impact factor: 2.778

8.  Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.

Authors:  A J Tiefenbrunn; A K Robinson; P B Kurnik; P A Ludbrook; B E Sobel
Journal:  Circulation       Date:  1985-01       Impact factor: 29.690
  8 in total
  4 in total

Review 1.  Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.

Authors:  H Ferres
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.

Authors:  J D Gemmill; K J Hogg; J M Burns; A P Rae; F G Dunn; R Fears; H Ferres; R Standring; H Greenwood; D Pierce
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 3.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

4.  Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.

Authors:  Rahat Kumar; Narinder Singh; Kartar Singh; Atul Kalhan; K K Prasad
Journal:  Indian J Clin Biochem       Date:  2004-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.